Group 1: M&A Activity - Brynwood Partners' CEO Henk Hartong III is looking to pursue more mergers and acquisitions (M&A) following the acquisition of Chef Boyardee, indicating a proactive approach in the current M&A environment [2] - The Nutriment Company, led by CEO Anders Kristiansen, is exploring M&A opportunities to drive sales growth, particularly in the fresh pet food sector [3] - Nomad Foods' venture arm, Future Foods Lab, is focused on "functional nutrition" and has a pipeline of acquisitions planned for the near future, with aspirations to reach $1 billion in revenue by 2025 [5] Group 2: Company Strategies and Market Focus - The Nutriment Company specializes in fresh pet food for dogs and cats and is expanding its presence in the European market, indicating a strategic focus on growth in this segment [3] - Holie, a company founded in 2018, has launched a range of better-for-you cereals and is expanding its market reach from the Netherlands and Belgium into the UK [4] - Captain Fresh's CEO David Suarez noted a decline in the plant-based meat category, attributing it to product quality issues, which suggests a need for improvement in this market segment [6]

Stanley Black & Decker, Inc. (NYSE:SWK) is one of the stocks Jim Cramer shared his take on. Cramer highlighted the company’s latest deal with Howmet, as he commented: “Finally, there’s the everybody wins kind of M&A. This morning, Stanley Black & Decker sold its aerospace manufacturing business, consolidated aerospace manufacturing to Howmet, a crackerjack aerospace company, for $1.8 billion in cash. This is a terrific deal for Stanley Black & Decker shareholders… because that company needs to repair its ...

Ovintiv Inc. (NYSE:OVV) is included among the 12 Best Crude Oil Stocks to Buy for Dividends. Ovintiv (OVV) Price Target Raised to $55 Ovintiv Inc. (NYSE:OVV) is a leading North American exploration and production company focused on developing its high-quality, multi-basin portfolio. On December 12, UBS slightly raised its price target on Ovintiv Inc. (NYSE:OVV) from $54 to $55, while maintaining a ‘Buy’ rating on the shares. The analyst noted that the energy sector seems well-positioned for a stronger 2 ...

I do want to talk more broadly though, get some insight on news that's shaped the markets this year, take a look at perhaps what we can expect in 2026. For that, we'll welcome in Pete Narian, the co-owner of Market Rebellion. Pete, great to have you back with us on the show.You know, let's talk about this rally. You sent over a couple notes in advance of our chat, and you referred to it as one of the most hated rallies you've ever seen. Why do you feel that way.>> I've been doing this since 1992, 1993, I th ...

Citigroup and Daiwa Securities Group are expanding their Japan investment banking teams as dealmaking accelerates amid governance reforms and changing attitudes to takeovers. Citigroup intends to lift headcount in its Japan investment banking unit by around 30% by the first half of 2026, the bank’s vice-chair for Japan Masuo Fukuda told Bloomberg. He did not disclose the current size of the team. Tokyo-based Daiwa has restarted overseas recruitment for merger advisory roles and is reinforcing its cross ...

In Brief Enterprise software company ServiceNow agreed to acquire a nine-year-old cybersecurity startup, Armis, for $7.75 billion in cash.The deal is a massive valuation jump for the company. Just last month, Armis raised a $435 million pre-IPO funding round, which valued the company at $6.1 billion. Armis co-founder and CEO Yevgeny Dibrov had told TechCrunch last month that the company aims to go public in late 2026 or 2027, adding that an IPO is his “personal dream.”Given the unpredictability of IPO mark ...

Key Takeaways AbbVie is rebounding post-Humira, with Skyrizi and Rinvoq sales up 53% Y/Y and expected to top $25B in 2025.AZN's newer drugs are driving growth as it targets $80B in revenues by 2030.Both face pressures: ABBV from aesthetics softness, AZN from China policy impacts and biosimilar erosion.AbbVie (ABBV) and AstraZeneca (AZN) are both global healthcare companies with diversified drug portfolios. Both companies have strong leadership positions in immunology and oncology areas.While AbbVie also has ...

Key Takeaways Large-cap pharma has beaten the S&P 500 lately as pricing deals, M&A and innovation revive investor sentiment.Eli Lilly, J&J, AbbVie, Amgen and AstraZeneca all posted strong 2025 gains on key drugs and pipeline. Despite patent cliffs and regulatory risks, innovation, AI use and deal momentum support a solid 2026 outlook.After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administrat ...

But what other kind of companies and industries may also be at play. Let's talk about it with Veto Sperdo. He is the head of RBC capital markets US global head co- global head of M&A.Veto, great to have you on. >> Thanks for having me. >> So what is the the deal making setup heading into 2026.>> Sure. Uh look, if I look back a year ago, we thought the first half was going to be a little slower just as people got used to the administration and the new policies and that's what played out. And then the second ...

As dealmakers welcomed 2025 with toasts at their Aspen and Palm Beach vacation homes, hopes were high that a business-friendly White House would usher in an M&A boom. Their champagne dreams mostly came true, though political volatility in DC proved an obstacle at times, too. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Backed by ‘Bank of Dad,’ Paramount Makes Another Push For Warner Bros. Discovery and Investors Hope the Santa Rally Is Hitching Up Its Reindeer Worthy of Br ...